ACRS
Aclaris Therapeutics, Inc.NASDAQHealthcare$4.20-9.52%ClosedMarket Cap: $506.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.52
P/S
58.56
EV/EBITDA
-6.42
DCF Value
$-1.08
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
73.3%
Operating Margin
-975.9%
Net Margin
-829.6%
ROE
-52.0%
ROA
-40.5%
ROIC
-57.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.3M | 162.0% | $-22.7M | $-19.8M | $-0.16 | — |
| FY 2025 | $7.8M | 73.3% | $-76.4M | $-64.9M | $-0.53 | — |
| Q3 2025 | $3.3M | 83.7% | $-17.1M | $-14.6M | $-0.12 | — |
| Q2 2025 | $1.8M | -4.1% | $-18.4M | $-15.4M | $-0.13 | — |
| Q1 2025 | $1.5M | 65.2% | $-18.1M | $-15.1M | $-0.12 | — |
| Q4 2024 | $9.2M | -1.0% | $-99.7M | $-96.6M | $-1.01 | — |
| FY 2024 | $18.7M | 85.1% | $-141.9M | $-132.1M | $-1.71 | — |
| Q3 2024 | $4.3M | 44.6% | $-10.5M | $-7.6M | $-0.11 | — |
| Q2 2024 | $2.8M | 31.0% | $-12.9M | $-11.0M | $-0.15 | — |
| Q1 2024 | $2.4M | 23.3% | $-18.9M | $-16.9M | $-0.24 | — |
| Q4 2023 | $17.6M | 63.4% | $-4.0M | $-1.5M | $-0.02 | — |
| FY 2023 | $31.2M | 42.1% | $-97.4M | $-88.5M | $-1.27 | — |